NCT03475056View on ClinicalTrials.gov

cAd3-Marburg Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 9, 2018

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
Marburg Virus Disease
Interventions
BIOLOGICAL

cAd3-Marburg vaccine

The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).

Trial Locations (1)

20910

WRAIR Clinical Trials Center,, Silver Spring

All Listed Sponsors
collaborator

US Military HIV Research Program

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03475056 - cAd3-Marburg Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter